Novo Nordisk A/S (NYSE:NVO) Shares Purchased by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 25.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,384 shares of the company’s stock after purchasing an additional 491 shares during the period. ZWJ Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $205,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NVO. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $98,765,000. Marshall Wace LLP increased its position in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after purchasing an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $42,017,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on NVO shares. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Up 2.9 %

NVO stock opened at $80.95 on Wednesday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The stock has a market capitalization of $363.25 billion, a PE ratio of 26.20, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a fifty day moving average of $97.15 and a 200-day moving average of $116.47.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.